Abstract Library

#3938 Brachytherapy in craniopharyngiomas: A systematic review and meta-analysis of long-term follow-up

Introduction: Brachytherapy has been indicated as an alternative option for treating cystic craniopharyngiomas (CPs). The potential benefits of brachytherapy for CPs have not yet been clarified. The purpose of this work was to conduct a meta-analysis to analyze the long-term efficacy and adverse reactions profile of brachytherapy for CPs.

Conference:

Presenting Author:

Authors: Zhang L, Guo W, Pan H,

Keywords: Brachytherapy, Craniopharyngiomas, Irradiation, Efficacy,

#3298 Adrenocortical carcinoma in the context of MEN1 patients with pNETS: From suspicion to diagnosis, management and follow-up

Introduction: Adrenocortical carcinoma (ACC) is a rare malignancy arising from adrenal parenchymal cells. Multiple endocrine neoplasia type 1 is an autosomal inherited predisposition cancer syndrome characterized by parathyroid hyperplasia, anterior pituitary gland tumors and pancreatic islet tumors. Although adrenal involvement in MEN1 patients has been reported in about 40% of patients, the incidence of ACC has been reported to range between 1,4% and 6% in MEN1.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Yiannakopoulou E,

Keywords: MEN1, pNETs, adrenocortical carcinoma,

#3255 The role of intraoperative ultrasound in pancreatic enucleation for pancreatic neuroendocrine tumors

Introduction: Pancreatic enucleation is an extreme pancreatic sparing procedure, characterized by the absence of dissection and reconstruction, minimal blood loss, but high rates of postoperative pancreatic fistula. Pancreatic enucleation is indicated for the treatment of insulinomas as well as small non-functioning pNETs. Intraoperative ultrasound is an essential tool for pancreatic enucleation.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Yiannakopoulou E,

Keywords: pancreatic enucleation, intraoperative ultrasound,

#34 Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust

Introduction: Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Teo L, Hearn K, Bernstone G, Wright R, Manus D,

Keywords: CgA, 5-HIAA, octreotide, lanreotide, prognosis, staging, neuroendocrine tumors,